BMY

#128
Bristol-Myers Squibb Company Common Stock
57.1 8 USD
+0.62%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
56.82
57.26
Rango anual
42.52
62.89
Cambio diario
+0.62%
Variación mensual
-0.92%
Variación en los últimos 6 meses
+15.94%
Cambio anual
+19.50%
Cierres anteriores
56.8 3
Open
56.9 0
Mínimo
56.8 2
High
57.2 6
Volumen
7 641
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 116.77 B
  • Employee 33 K
  • Founded N/A
  • CEO Chris Boerner
  • Website www.bms.com
  • Headquarter Delaware, United States
  • FIGI BBG000DQLV23
  • Industry Fabricantes de medicamentos — general
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
16.99
Relación precio/flujo de caja
2.55
Dividendos por acción
0.63
Rendimiento por dividendo, %
7.19

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

Noticias